Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)

10
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

09/08/2011 | 10:10pm US/Eastern

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

React to this article
Latest news on ASTELLAS PHARMA INC
07/01 ASTELLAS PHARMA : Studies from Astellas Pharma, Inc. Have Provided New Data on P..
07/01 ASTELLAS PHARMA : Reports Outline Medicinal Chemistry Findings from Astellas Pha..
07/01 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares; (Under the prov..
06/30 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 63KB)
06/20 CYTOKINETICS : Presents Results From Phase I Studies of CK-2127107
06/17 ASTELLAS PHARMA : Patent Issued for Amido Derivatives-Contained Pharmaceutical C..
06/17 ASTELLAS PHARMA : Study Results from Astellas Pharma, Inc. Broaden Understanding..
06/16 ASTELLAS PHARMA : announces preliminary phase 1/2 safety, tolerability and effic..
06/15 ASTELLAS PHARMA : Employees Assemble Thousands Of Care Packages For Homeless Vet..
06/15 ASTELLAS PHARMA : Results of Additional Analysis of Data from Japanese Clinical ..
Advertisement
Chart
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Income Statement Evolution
More Financials